METHOD FOR EMERGENCY PREVENTION AND TREATMENT OF ACUTE RADIATION SICKNESS (VERSIONS) Russian patent published in 2019 - IPC A61K38/18 A61P39/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to radiation medicine, and can be used for prevention and treatment of acute radiation sickness (ARS). First version of the method involves administering a liposomal preparation containing recombinant human alpha-protein (rhAFP) in amount of 0.1–1.0 mg/ml intravenously once after irradiation in a dose of up to 10 mg/kg of body weight in terms of rhAFP or same dose according to scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. Second version of the method involves administering a liposomal preparation containing a recombinant human granulocyte colony-stimulating factor (rhGCSF) in amount of 0.004–0.06 mg/ml intravenously once immediately after irradiation in a dose of up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same dose according to the scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. In the third version, the acute prevention and treatment of acute radiation sickness is accompanied by administering a liposomal preparation containing rhAFP in amount of 0.1–1.0 mg/ml and rhGCSF in amount of 0.004–0.06 mg/ml. This preparation is administered intravenously once immediately after irradiation in dose of 10 mg/kg of body weight in terms of rhAFP and up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same doses according to the scheme: immediately after irradiation and after 1, 3, 5, 7 days after irradiation.

EFFECT: use of the inventions enables the prevention and treatment of ARS by regulating growth, development and programmed death of hematopoietic stem cells, differentiation and activation of immune cells, stimulation of proliferation and maturation of granulocyte-containing blood leukocytes, as well as repair of radiation-damaged cell membranes.

3 cl, 4 tbl, 2 ex